BioSpace News Archive

− Initiation of Phase 3 Objective Sign Trial in Dry Eye Disease Planned for the Fourth Quarter 2020 − Phase 2 Clinical Trials of ADX-629 in COVID-19, Atopic Asthma, and Psoriasis Expected to Initiate in the Fourth Quarter of 2020 − Top-line Results from the Phase 3 INVIGORATE Clinical Trial in Allergic Conjunctivitis Expected in the First Half of 2021 − Cash, Cash Equivalents, and Marketable Securities of $86.2 Million as of September 30

Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter financial results for the period ended September 30, 2020, on Monday, November 9, 2020, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Deta

Phase 3 DISSOLVE clinical program with Sobi ongoing to evaluate SEL-212; topline data expected in the second half of 2022 IND filing for gene therapy expected in Q1 2021; preliminary Phase 1 data expected by end of 2021 IgA nephropathy program underway with IND expected by end of 2021 Ended quarter with cash position of $147.6 million with runway into the first quarter of 2023 Company to host conference call today at 8:30 a.m. ET

Results from an ongoing Phase 1a/1b clinical trial for Arbutus’ AB-729, a subcutaneously delivered RNAi agent, in subjects with chronic hepatitis B virus (HBV) infection, to be presented at the upcoming American Association for the Study of Liver Disease (AASLD) Conference

- Successful Financings, including $268 Million Initial Public Offering and $116 Million Series B Expected to Fund Through Proof of Concept Data in Co-lead Programs, Myotonic Dystrophy Type 1 and Duchenne Muscular Dystrophy -

BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it will release third quarter 2020 financial and operating results on Thursday, November 12, 2020 after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET /

Crescita Therapeutics Inc. today announced that it has entered into an exclusive agreement with Juyou-Biotechnology Co. Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products

Endo International plc (NASDAQ: ENDP) today announced the initiation of several strategic actions to further optimize the Company’s operations and increase overall efficiency. These actions are expected to generate significant cost savings that will be reinvested,

18 abstracts spanning Jazz’s hematology/oncology therapeutic area to be presented Three abstracts selected for oral presentation, including long-term results from a Phase 3 study of Vyxeos in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the third quarter ended September 30, 2020 after the close of the market on Thursday, November 12, 2020.